Lumiracoxib 400 mg Compared With Celecoxib 400 mg and Placebo for Treating Pain Following Dental Surgery: A Randomized, Controlled Trial

Fricke, James R.; Davis, Nicole L.; Yu, Vincent; Krammer, Gerhard

doi:10.1016/j.jpain.2007.08.004

Cited by 12 publications

(26 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…4 There was only one withdrawal in one study. 6 This patient had been allocated to an ibuprofen group and presented postoperative bleeding at the suture site, but no association with the drug was reported.…”

Section: Adverse Eventsmentioning

confidence: 98%

“…3 Acute dental pain and postoperative pain are often treated with analgesics and non-steroidal anti-inflammatory drugs (NSAIDs) such as paracetamol, ibuprofen, rofecoxib and celecoxib. [4][5][6] The efficacy of these drugs in reducing inflammation and pain is largely attributed to prevention of prostaglandin synthesis via non-specific inhibition of both cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2). 5 Lumiracoxib is a new selective inhibitor of COX-2 that was also developed for treating acute pain.…”

Section: Introductionmentioning

confidence: 99%

“…6 The second one compared lumiracoxib 400 mg with rofecoxib 50 mg, celecoxib 200 mg and placebo, and 5 The third compared lumiracoxib 400 mg with celecoxib 400 mg and placebo, and assessed 364 patients. 4 These studies were all carried out in the United States with financial support from the pharmaceutical industry. The overall flow chart of the studies is presented in Figure 1.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Lumiracoxib for acute postoperative dental pain: a systematic review of randomized clinical trials

Silva¹,

Riera

Saconato

2011

Sao Paulo Med. J.

View full text Add to dashboard Cite

CONTEXT AND OBJECTIVE: Lumiracoxib is an anti-inflammatory drug that has been used to treat acute dental pain, mainly in postsurgical settings, in which the greatest levels of pain and discomfort are experienced during the first 24 hours. This study aimed to assess the efficacy and safety of lumiracoxib for treating acute postsurgical dental pain. DESIGN AND SETTING: Systematic review developed at the Brazilian Cochrane Centre, Universidade Federal de São Paulo. METHODS: An electronic search was conducted in the PubMed, Cochrane Library, Lilacs (Literatura Latino-Americana e do Caribe em Ciências da Saúde), SciELO (Scientific Electronic Library Online) and Embase databases. A manual search was also performed. Only randomized controlled trials were included, and these were selected and assessed by two researchers with regard to the risk of bias. RESULTS: Three clinical trials with 921 participants were included. Lumiracoxib 400 mg produced onset of analgesia in a shorter time than shown by lumiracoxib 100 mg, celecoxib 200 mg and ibuprofen 400 mg. There was no difference between lumiracoxib 400 mg and rofecoxib 50 mg. In two studies, the mean time taken to attain onset of analgesia for the placebo was not estimated because the number of participants who reached onset was too small. CONCLUSION: There is evidence with a moderate risk of bias that recommends the use of lumiracoxib for acute postoperative dental pain. However, the adverse effects are not completely known. Given that lumiracoxib is currently available in only three countries, further studies are likely to be rare and discouraged.reSUmO CONTEXTO E OBJETIVO: O lumiracoxibe é um anti-inflamatório que tem sido utilizado no tratamento de dor dental aguda, principalmente no cenário pós-cirúrgico, no qual níveis mais elevados de dor e desconforto são sentidos durante as primeiras 24 horas. Este estudo teve por objetivo avaliar a eficácia e a segurança do lumiracoxibe no tratamento da dor dental aguda e pós-operatória.

show abstract

Section: Adverse Eventsmentioning

confidence: 98%

Section: Introductionmentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

Lumiracoxib for acute postoperative dental pain: a systematic review of randomized clinical trials

Silva¹,

Riera

Saconato

2011

Sao Paulo Med. J.

View full text Add to dashboard Cite

show abstract

“…(Zelenakas et al, 2004;Fricke et al, 2008) and, to the best of our knowledge, this is the first paper to compare this drug efficacy with diclofenac, which is largely utilized in Brazilian dental treatments.…”

Section: Nícoli G A; Conte-neto N; Campos J á D B; Cabrini-mentioning

confidence: 99%

Efficacy of Lumiracoxib Versus Diclofenac Sodium in Pain Control Following Extraction of Impacted Lower Third Molar

Nícoli

Neto

Campos

et al. 2017

Int. J. Odontostomat.

View full text Add to dashboard Cite

ABSTRACT:The aim of this paper was to compare the efficacy of two different anti-inflammatory agents, Diclofenac (Deltaflogin ® ) and Lumiracoxib (Prexige ® ) in the control of postoperative pain that results from surgical removal of impacted lower third molars. Twenty adult patients from the Oral and Maxillofacial Surgery Division of the Araraquara Dentistry School, UNESP who presented bilateral impacted lower third molars were included in the study. Removal of the impacted teeth was performed in each side in different operative moments in a split mouth design for the study. The anti-inflammatory drugs evaluated were randomly administered on the first and second surgical procedures. The pain level was recorded using an analogical visual scale at 6, 24, 48 and 72 hours after surgical intervention. Both lumiracoxib 400 mg and diclofenac 100 mg are efficient for acute pain control after surgical removal of impacted lower third molars. However, lumiracoxib offered better pain control.

show abstract

“…Single-dose POC trials have been used to examine many treatments for acute pain, including pain from dental procedures [17,35], dysmenorrhea [13,75], and sore throat pain [106]. The single session nature of this study makes it very efficient compared with multiple-dose studies lasting weeks or months for those treatments that are expected to have a prompt onset of analgesic effect.…”

Section: Designsmentioning

confidence: 99%

Research designs for proof-of-concept chronic pain clinical trials: IMMPACT recommendations

Gewandter

Dworkin

Turk

et al. 2014

Pain

105

View full text Add to dashboard Cite

Lumiracoxib 400 mg Compared With Celecoxib 400 mg and Placebo for Treating Pain Following Dental Surgery: A Randomized, Controlled Trial

Cited by 12 publications

References 19 publications

Lumiracoxib for acute postoperative dental pain: a systematic review of randomized clinical trials

Lumiracoxib for acute postoperative dental pain: a systematic review of randomized clinical trials

Efficacy of Lumiracoxib Versus Diclofenac Sodium in Pain Control Following Extraction of Impacted Lower Third Molar

Research designs for proof-of-concept chronic pain clinical trials: IMMPACT recommendations

Contact Info

Product

Resources

About